Skip Navigation

Details for High Impact Journal

Maintenance notice: We are currently addressing issues with broken links due to recent major website changes. We apologize for any inconvenience and appreciate your patience. Please contact brittany.trottier@niehs.nih.gov for assistance.

Superfund Research Program

Gut (impact factor: 23.059)

2023

  • Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gomez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison SA, Younossi Z, Myers RP. 2023. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 72(3):581-589. doi:10.1136/gutjnl-2022-327777 PMID:36750244 PMCID:PMC9905707

2022

  • Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB and Loomba R. 2022. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 71:983-990. doi:10.1136/gutjnl-2021-324264 PMID:33883248 PMCID:PMC8594562

2021

  • Jung J, Loomba RR, Imajo K, Madamba E, Gandhi S, Bettencourt R, Singh S, Hernandez C, Valasek MA, Behling C, Richards L, Fowler K, Sirlin CB, Nakajima A, Loomba R. 2021. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 70:1946-1953. doi:10.1136/gutjnl-2020-322976 PMID:33214165 PMCID:PMC8131405

2020

2019

  • Wang P, Wang Y, Langley SA, Zhou Y, Jen K, Sun Q, Brislawn C, Rojas CM, Wahl KL, Wang T, Fan X, Jansson J, Celniker SE, Zou X, Threadgill DW, Snijders AM, Mao J. 2019. Diverse tumour susceptibility in Collaborative Cross mice: Identification of a new mouse model for human gastric tumourigenesis. Gut doi:10.1136/gutjnl-2018-316691 PMID:30842212

2012

Back
to Top